NCT05688345 is a Phase 4 clinical trial of Remimazolam in Remimazolam, sponsored by Asan Medical Center.

Who is sponsoring NCT05688345?

NCT05688345 is sponsored by Asan Medical Center.

What drugs are being tested in NCT05688345?

Interventions in NCT05688345: Remimazolam, Propofol, Dexmedetomidine.

What condition does NCT05688345 study?

NCT05688345 studies Remimazolam, Propofol, Dexmedetomidine, Orthopedic Procedures, Sedatives, Brachial Plexus Block.

Is NCT05688345 still recruiting?

NCT05688345 is currently completed. Last updated 31 January 2024.

Last reviewed 2024-01-31 · How we verify

NCT05688345

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Recovery Profiles Among Propofol, Remimazolam, and Dexmedetomidine After Intraoperative Sedation

Completed Phase 4 Last updated 31 January 2024

What this trial tests

Phase 4 trial testing Remimazolam in Remimazolam in 120 participants. Completed in 13 August 2023.

Timeline

23 February 2023

Primary endpoint
12 August 2023

13 August 2023

Quick facts

Lead sponsor	Asan Medical Center
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	120
Start date	23 February 2023
Primary completion	12 August 2023
Estimated completion	13 August 2023
Sites	1 location across South Korea

Drugs / interventions tested

Remimazolam — full drug profile →
Propofol (Propofol) — full drug profile →
Dexmedetomidine (dexmedetomidine) — full drug profile →

Conditions studied

Remimazolam — all drugs for Remimazolam →
Propofol — all drugs for Propofol →
Dexmedetomidine — all drugs for Dexmedetomidine →
Orthopedic Procedures — all drugs for Orthopedic Procedures →

Sponsor

Asan Medical Center

Who can join

Adults 19 to 80, any sex, with Remimazolam or Propofol. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A total of 120 patients (American Society of Anesthesiologist Physical Status 1-3) who signed a consent form among patients aged 19-80 years who are scheduled to undergo brachial plexus block and upper extremity surgery under monitored anesthetic care at our hospital were enrolled. Recruited patients are divided into three groups through computer-generated randomization by using the patient identification number assigned during patient recruitment. (40 people in each group) Standard monitoring is performed when the patient arrives at the operating room. Patients receive oxygen at 5-6 L/min using a simple facial mask, and receive a brachial plexus block under ultrasound guidance. After confirming the success of brachial plexus block, administration of propofol, remimazolam, or dexmedetomidine is started according to the assigned group. Assess the patient's level of consciousness through the MOAA/S (modified observer's assessment of alertness/sedation scale) scale. The drug injection ends when the skin suture is started after the main procedure. The time from the end of injection of each drug until MOAA/S becomes 5 points is measured. After the patient is transferred to the recovery room, the Aldrete score is assessed. The recovery profile, perioperative hemodynamic change, desaturation event, block duration, patient movement during surgery, patient satisfaction, and surgeon's satisfaction were investigated and analyzed for comparison.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Comparison of the recovery profiles of propofol, dexmedetomidine, and remimazolam for intraoperative sedation in patients undergoing upper limb surgery under brachial plexus blockade: a randomized controlled trial.
Kim HJ, Kim YJ, Lee J, Jeong D, et al · · 2025 · cited 2× · PMID 40514628 · DOI 10.1007/s12630-025-02987-3

Verify or expand the search:

Other trials of Remimazolam

Trials testing the same drug.

NCT07251101 — Hemodynamic Effects of Remimazolam vs Propofol During Robot-assisted Gynecologic Surgery · NA · not yet recruiting
NCT07459322 — The Use of Remimazolam Versus Dexmedetomidine for Patients Receiving Drug-Induced Sleep Endoscopy · NA · not yet recruiting
NCT07290205 — Remimazolam NeuroImaging · EARLY_PHASE1 · recruiting
NCT07269808 — Sedation During Endoscopy Using Remimazolam: Efficacy in a Novel Exploration · Phase 3 · recruiting
NCT06231563 — Ketamine for Veterans With Parkinson's Disease · Phase 2 · recruiting

Other recruiting trials for Remimazolam

Currently open trials in the same condition.

NCT07290205 — Remimazolam NeuroImaging · EARLY_PHASE1 · recruiting
NCT07050212 — Application of Remimazolam, Dexmedetomidine, and Esketamine in Pediatric Preoperative Sedation · NA · recruiting
NCT06716840 — Remimazolam Besylate in Sedation of Postcardioperative Patients · NA · recruiting
NCT07046364 — Remimazolam and Emergence Delirium in Pediatrics · Phase 4 · recruiting
NCT06698705 — The EEG Study Under Remimazolam Anesthesia in Children · recruiting

Other Asan Medical Center trials

Trials by the same sponsor.

NCT07530393 — Blood Viscosity and Outcomes After Elective Craniotomy · not yet recruiting
NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
NCT07382505 — Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cerv · not yet recruiting
NCT07489092 — Feasibility of a Digital Rehabilitation Platform in Patients After ICU Discharge · NA · recruiting
NCT07431762 — Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Hear · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05688345 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Asan Medical Center
Last refreshed: 31 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05688345.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing